去纤维钠是什么？

What is it? For many domestic patients with hepatic veno-occlusive disease, the name defibrotide sodium is relatively unfamiliar. It is also called defibrotide. It is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). It was approved for marketing in the EU in 2013, bringing new treatment options to HVOD patients.

In 2016, defibrotide sodium (defibrotide) was approved for marketing in the United States. It is the first drug approved by the US FDA to treat severe hepatic veno-occlusive disease. It is used for patients, including adults or children, with hepatic venous obstruction (HVOD) after blood or bone marrow hematopoietic stem cell transplantation (HSCT) and accompanied by renal or lung function abnormalities, including adults or children. The drug has also received "orphan drug" qualifications.

Defibrotide sodium (defibrinoside) is a drug that requires injection, and patients must use it strictly in accordance with the doctor's judgment. Defibrotide sodium is used in dilute doses based on body weight. The recommended dose is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Prior to dosing, determine that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressin. Do not coadminister with other intravenous medications at the same time and in the same intravenous line.

Studies have shown that defibrotide sodium (defibrinoside) mainly exerts various biological functions by affecting vascular endothelial cell response and platelet activity. Defibrinated sodium contains nucleic acid aptamers that interact with adenosine A1 and A2 receptors, thereby reducing the response of endothelial cells to injury and protecting vascular endothelium. In clinical trials, defibrinated sodium has also shown positive effects, effectively reducing the incidence of HVOD, and more and more patients have benefited from it.

The above is the introduction of the drug. Its use can effectively prolong the survival time of patients with hepatic veno-occlusive disease and is a good choice for patients.